Compare TRX & CTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TRX | CTMX |
|---|---|---|
| Founded | 1990 | 2008 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 228.9M | 596.2M |
| IPO Year | N/A | 2015 |
| Metric | TRX | CTMX |
|---|---|---|
| Price | $0.90 | $4.12 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | $1.25 | ★ $6.50 |
| AVG Volume (30 Days) | 1.4M | ★ 2.1M |
| Earning Date | 01-13-2026 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 50.22 |
| EPS | 0.00 | ★ 0.24 |
| Revenue | $57,613,000.00 | ★ $113,631,000.00 |
| Revenue This Year | $28.16 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $363.98 | ★ $17.49 |
| Revenue Growth | ★ 39.98 | N/A |
| 52 Week Low | $0.27 | $0.40 |
| 52 Week High | $0.89 | $4.62 |
| Indicator | TRX | CTMX |
|---|---|---|
| Relative Strength Index (RSI) | 72.25 | 56.75 |
| Support Level | $0.82 | $3.78 |
| Resistance Level | $0.89 | $4.20 |
| Average True Range (ATR) | 0.05 | 0.23 |
| MACD | 0.02 | -0.01 |
| Stochastic Oscillator | 98.21 | 72.39 |
TRX Gold Corp is a mineral resource company. It is engaged in the acquisition of interests and the exploration of natural resource properties. Its mineral properties are located in the United Republic of Tanzania. The company's main area of interest has been in the exploration and development of gold properties. It is focused on the Buckreef Gold Project which comprises five prospects, namely Buckreef, Bingwa, Tembo, Eastern Porphyry, and Buziba.
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.